References

Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: a systematic review and meta-analysis

10.1002/alz.70828 · 2025 · External reference

Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

10.1016/s1474-4422(25)00227-3 · 2025 · External reference

Lecanemab: appropriate use recommendations

10.14283/jpad.2023.30 · 2023 · External reference

Donanemab: appropriate use recommendations

10.1016/j.tjpad.2025.100150 · 2025 · External reference

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

10.1002/alz.13859 · 2024 · External reference

Alzheimer disease as a clinical-biological construct—an International Working Group Recommendation

10.1001/jamaneurol.2024.3770 · 2024 · External reference

Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer's Disease

10.1038/s41582-024-00977-5 · 2024 · External reference

Biomarker-guided decision making in clinical drug development for neurodegenerative disorders

10.1038/s41573-025-01165-w · 2025 · External reference

Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles

10.1038/s43587-023-00550-7 · 2024 · External reference

A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research

10.1016/s1474-4422(23)00405-2 · 2024 · External reference

10.1016/s1474-4422(26)00285-1 · 2026 · Admitted local publication

10.1016/s1474-4422(26)00248-6 · 2026 · Admitted local publication

Blood biomarkers to detect Alzheimer disease in primary care and secondary care

10.1001/jama.2024.13855 · 2024 · External reference

Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease

10.1002/alz.14150 · 2024 · External reference

Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias

10.1038/s41586-025-10018-w · 2026 · External reference

Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly

10.1186/s13195-025-01925-1 · 2025 · External reference

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

10.1002/alz.14088 · 2024 · External reference

Detection of Alzheimer neuropathology in Alzheimer and non-Alzheimer clinical syndromes with blood-based biomarkers

10.1001/jamaneurol.2024.5017 · 2025 · External reference

Performance of plasma p-tau217 and NfL in an unselected memory clinic setting

2024 · External reference

Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

10.1038/s41467-021-23746-0 · 2021 · External reference

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

10.1038/s41591-021-01348-z · 2021 · External reference

Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial

10.1001/jama.2023.13239 · 2023 · External reference

Clinical use of biomarkers in the era of Alzheimer's disease treatments

10.1002/alz.14201 · 2025 · External reference

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability

10.1038/s43587-024-00731-y · 2024 · External reference

Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings

10.1002/alz.70535 · 2025 · External reference

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology

10.1002/alz.14315 · 2024 · External reference

Biomarker-guided decision making in clinical drug development for neurodegenerative disorders

10.1038/s41573-025-01165-w · 2025 · External reference

Primary age-related tauopathy (PART): a common pathology associated with human aging

10.1007/s00401-014-1349-0 · 2014 · External reference

Frontotemporal dementia

10.1016/s1474-4422(05)70223-4 · 2005 · External reference

Tau protein and frontotemporal dementias

2021 · External reference

The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies

10.1007/s00401-020-02157-3 · 2020 · External reference

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report

10.1093/brain/awz099 · 2019 · External reference

Chronic effects of inflammation on tauopathies

10.1016/s1474-4422(23)00038-8 · 2023 · External reference

Role of neuroinflammation in neurodegeneration development

10.1038/s41392-023-01486-5 · 2023 · External reference

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

10.1038/s41582-020-00435-y · 2021 · External reference

Ageing as a risk factor for neurodegenerative disease

10.1038/s41582-019-0244-7 · 2019 · External reference

Polygenic risk scores in neurodegenerative diseases: a review

10.1007/s40142-019-0158-0 · 2019 · External reference

Association of plasma and cerebrospinal fluid Alzheimer disease biomarkers with race and the role of genetic ancestry, vascular comorbidities, and neighborhood factors

10.1001/jamanetworkopen.2022.35068 · 2022 · External reference

Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases

10.3389/fncel.2015.00124 · 2015 · External reference

The global burden of neurological disorders: translating evidence into policy

10.1016/s1474-4422(19)30411-9 · 2020 · External reference

Proteomics of protein post-translational modifications implicated in neurodegeneration

10.1186/2047-9158-3-23 · 2014 · External reference

Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids

10.1038/s41586-023-06437-2 · 2023 · External reference

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

10.1016/s1474-4422(21)00361-6 · 2022 · External reference

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease

10.1038/s41591-020-0781-z · 2020 · External reference

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease

10.1038/s41591-025-03617-7 · 2025 · External reference

Detecting alpha-synuclein aggregates with small molecules on single-molecule array

10.1039/d4sc07649d · 2025 · External reference

A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders

10.1038/s41591-026-04212-0 · 2026 · External reference

Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration

10.1093/brain/awac407 · 2023 · External reference

Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

10.1038/s41591-024-02937-4 · 2024 · External reference

A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD

10.1038/s41591-023-02788-5 · 2024 · External reference

Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD

10.1126/scitranslmed.adg7162 · 2024 · External reference

An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration

10.1038/s41591-026-04341-6 · 2026 · External reference

Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: results and consensus of the Global Biomarker Standardization Consortium

10.1002/alz.70752 · 2025 · External reference

Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study

10.1016/s1474-4422(26)00029-3 · 2026 · External reference

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease

10.1093/brain/awab223 · 2021 · External reference

Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease

10.1016/j.jalz.2018.03.005 · 2018 · External reference

Plasma phosphorylated tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment

10.1001/jamaneurol.2024.2619 · 2024 · External reference

Discovery of novel CSF biomarkers to predict progression in dementia using machine learning

10.1038/s41598-023-33045-x · 2023 · External reference

Prognostic value of blood-based p-tau217 levels for progression to cognitive impairment

10.1001/jama.2026.12556 · 2026 · External reference

Microglia protein profiles in CSF across Alzheimer's disease clinical stages

10.1038/s43587-026-01088-0 · 2026 · External reference

Multimorbidity and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies

10.1016/j.tjpad.2025.100164 · 2025 · External reference

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

10.1016/j.jalz.2019.04.001 · 2019 · External reference

Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis

10.1186/s13195-018-0459-7 · 2019 · External reference

Prediction models for conversion from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis

10.3389/fnagi.2022.840386 · 2022 · External reference

Predicting cognitive decline in amyloid-positive patients with mild cognitive impairment or mild dementia

10.1212/wnl.0000000000209605 · 2024 · External reference

Association of CSF α-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer's Disease Neuroimaging Initiative study

10.1002/alz.14276 · 2024 · External reference

Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling

10.1038/s43587-026-01081-7 · 2026 · External reference

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients

10.1186/s13195-025-01799-3 · 2025 · External reference

Limited generalizability and high risk of bias in multivariable models predicting conversion risk from mild cognitive impairment to dementia: a systematic review

10.1002/alz.70069 · 2025 · External reference

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project

10.1186/s13195-019-0487-y · 2019 · External reference

Interpreting biomarker results in individual patients with mild cognitive impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project

10.1001/jamaneurol.2017.2712 · 2017 · External reference

Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study

10.1016/s1474-4422(25)00350-3 · 2025 · External reference

A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease

10.1038/s41591-025-03565-2 · 2025 · External reference

A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia

10.1038/s41591-026-04303-y · 2026 · External reference

Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial

10.1001/jamaneurol.2022.3392 · 2022 · External reference

Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study

10.1002/alz.71231 · 2026 · External reference

Plasma biomarkers for cerebral amyloid angiopathy and implications for amyloid-related imaging abnormalities: a comprehensive review

10.3390/jcm14041070 · 2025 · External reference

Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots—a new collection method for remote settings

10.1002/alz.13697 · 2024 · External reference

Alzheimer's Association launches ALZ-NET: A long-term data collection and sharing network for new treatments

10.1002/alz.12782 · 2022 · External reference

Dementia registries around the globe and their applications: a systematic review

10.1016/j.jalz.2017.04.005 · 2017 · External reference

Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance

10.1186/s13195-025-01699-6 · 2025 · External reference

Response to Xing et al. Post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database

10.1186/s13195-025-01735-5 · 2025 · External reference

Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease

10.1002/alz.13431 · 2024 · External reference

Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay

10.1002/alz.13658 · 2024 · External reference

Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease

10.1186/s13024-025-00822-3 · 2025 · External reference

Tau-clinical mismatch identifies individuals with co-pathology and predicts clinical trajectory

2025 · External reference

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review

10.1186/s13195-024-01456-1 · 2024 · External reference

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease

10.1038/s41591-023-02443-z · 2023 · External reference

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

10.1002/ana.1054 · 2001 · External reference

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

10.1016/s1474-4422(21)00214-3 · 2021 · External reference

Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein

10.1126/scitranslmed.3006446 · 2013 · External reference

Tau kinetics in neurons and the human central nervous system

10.1016/j.neuron.2018.04.035 · 2018 · External reference

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels

10.1186/s40478-021-01307-2 · 2022 · External reference

Early Alzheimer's Disease with frequent neuritic plaques harbors neocortical tau seeds distinct from primary age-related tauopathy

10.1038/s41467-025-56469-7 · 2025 · External reference

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

10.15252/emmm.202114022 · 2021 · External reference

Lecanemab in early Alzheimer's disease

10.1056/nejmoa2212948 · 2023 · External reference

Clinical validation of plasma p-217tau in neurological diseases

10.1002/acn3.70359 · 2026 · External reference

ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression

10.1002/acn3.70001 · 2025 · External reference

Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis

10.1038/s41591-026-04272-2 · 2026 · External reference

Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration

10.1093/brain/awx339 · 2018 · External reference

Evidence that minocycline treatment confounds the interpretation of neurofilament as a biomarker

10.1093/braincomms/fcaf175 · 2025 · External reference